Joints Dietary supplementBoswellia serrata Resin (Indian Frankincense)

Boswellia

Boswellia serrata · Frankincense Extract

Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.

300-500mg standardized extract – 500-1000 mg Oral 1-3x daily

5-Lipoxygenase InhibitorAnti-Inflammatory BotanicalAyurvedic Medicine

Boswellia (Boswellia serrata, also known as Indian Frankincense) is a tree resin extract used in Ayurvedic medicine for centuries. Active compounds are boswellic acids, particularly AKBA (3-O-acetyl-11-keto-β-boswellic acid) - a potent and selective 5-lipoxygenase inhibitor that reduces leukotriene-mediated inflammation.

Quick Start

Route

Oral capsule

Start low

300-500mg Oral

Frequency

1-3x daily

Timing

With food

Starting dose. 300-500mg — Standardized extract

Independent.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

300-500mg standardized extract · Oral capsule · 1-3x daily

conservative starter

300-500mg standardized extract

1-3x daily

Standard

Joint & Systemic Anti-Inflammatory

500-1000 mg · Oral · 2x Daily

human clinical trial · Kimmatkar et al. 2003 (Phytomedicine)

Look for extracts standardized to AKBA (acetyl-11-keto-beta-boswellic acid), the primary active component.

500-1000 mg

2x Daily

◆

How it works

Boswellia acts via boswellic acids:

AKBA 5-LOX Inhibition

AKBA selectively inhibits 5-lipoxygenase, reducing leukotriene B4 and other pro-inflammatory leukotrienes - distinct from NSAIDs (which inhibit COX). Complementary mechanism.

NF-κB Modulation

Boswellic acids reduce NF-κB activation, decreasing inflammatory cytokine production.

Cathepsin G Inhibition

Reduces neutrophil-mediated tissue damage.

Synovial Fluid Effects

Improves joint synovial fluid composition in OA.

Better GI Tolerance

Unlike NSAIDs (COX inhibition causes GI ulceration), boswellia's 5-LOX mechanism doesn't compromise gastric protection.

What to expect

Early

Days 1–7

Days 1-14: subtle effects.

Mid

Weeks 2–4

Weeks 4-8: peak benefits.

Later

Weeks 4–12

Long-term continuous use OK.

Evidence

HumanModerate

AnimalStrong

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Effect boundary: in a 120-day pilot RCT (n=48 knee-osteoarthritis patients), a Boswellia serrata extract containing both AKBBA and BBA reduced pain, improved physical function, and lowered serum hs-CRP versus placebo. The trial authors attributed this to synergy between the two constituents, but the whole-extract-vs-placebo design did not test the constituents separately, so true pharmacological synergy has not been demonstrated.

The findings provide evidence that biologically active constituents of BSE, namely, AKBBA and BBA, act synergistically to exert anti-inflammatory/anti-arthritic activity showing improvement in physical and functional ability and reducing the pain and stiffness.

A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytotherapy research : PTR · 2019 · PMID 30838706

Evidence scope. Human RCT, n=48 knee-OA patients (disease population, not healthy), oral, 120 days; industry-affiliated trial; 2-arm design cannot isolate constituent-level synergy.

Dose/route: standardized Boswellia serrata extract was given orally at 150 or 300 mg twice daily; 300 mg twice daily lies within the card’s 300-500 mg 1-3x/day range.

Based on the inclusion/exclusion criteria, 105 newly diagnosed participants with degenerative hypertrophy OA were recruited and randomized into Placebo, BSE-150 mg or BSE-300 mg (n = 35 in each group) to receive either 150 mg or 300 mg BSE or a placebo tablet twice a day for 90 days.

A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial. Frontiers in pharmacology · 2024 · PMID 39092235

Evidence scope. Human RCT, n=105 (35/arm) newly diagnosed knee-OA patients, oral tablet, 90 days; same manufacturer-affiliated research group as PMID 30838706.

Primary safety: no significant adverse events were recorded in the 90-day 150/300 mg twice-daily trial.

No significant adverse events were recorded during the study.

Evidence scope. Same trial as above: human knee-OA patients, n=105 (98 completers), oral, 90 days — moderate size/duration, industry-affiliated.

Side effects & safety

Commonly reported

Mild GI
Mild headache rare

Less common & notes

Mild antiplatelet activity.
Allergic reactions rare.
Long-term safety good per Ayurvedic use.

Pharmacokinetics

Illustrative plasma concentration · 19 h

Half-life

AKBA ~6 hours

Peak · Tmax

2-4 hours

Post-ingestion

Elimination

Daily dosing for sustained effect

Bioavailability

Oral moderate

Duration of action

Daily dosing for sustained effects

Clearance

Hepatic

Storage. Capsule. Cool dry location.

Regulatory status

Dietary supplement (US, DSHEA). Ayurvedic medicine.

Put it to work

Calculate, log & track

Open Boswellia straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Boswellia in the app →

Go deeper

The guide & community

The complete Boswellia walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community